azacitidine has been researched along with entinostat in 30 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 6 (20.00) | 29.6817 |
| 2010's | 21 (70.00) | 24.3611 |
| 2020's | 3 (10.00) | 2.80 |
| Authors | Studies |
|---|---|
| Davis, MI; Khan, J; Li, SQ; Patel, PR; Shen, M; Sun, H; Thomas, CJ | 1 |
| Dranchak, PK; Huang, R; Inglese, J; Lamy, L; Oliphant, E; Queme, B; Tao, D; Wang, Y; Xia, M | 1 |
| Erdlenbruch, B; Kanbach, K; Monkemeyer, S; Pekrun, A; Reinhardt, D; Rönndahl, G; Witt, O | 1 |
| Bergeron, A; Fradet, Y; Larue, H; Picard, V | 1 |
| Boklan, J; Chandra, J; Gao, S; Miller, C; Mobley, A | 1 |
| Farzaneh, F; Gaymes, TJ; Lea, NC; MacPherson, LJ; Mufti, GJ; Shall, S; Twine, NA | 1 |
| Aucott, T; Carraway, HE; Choi, SH; Dauses, T; Espinoza-Delgado, I; Fandy, TE; Gore, SD; Herman, JG; Jiemjit, A; Kerns, P; Kim, MK; Licht, J; McConnell, MJ; Murgo, A; Nasrallah, C; Odchimar-Reissig, R; Oteiza, K; Owoeye, I; Silverman, LR; Sugar, EA; Sun, Y; Yang, AS; Zhang, W | 1 |
| Bartlett, DL; Gorry, MC; Guo, ZS; Li, Q; O'Malley, ME | 1 |
| Baylin, SB; Belinsky, SA; Casero, RA; Channell, MM; Grimes, MJ; Liu, Y; March, TH; Mitchell, HD; Picchi, MA; Reed, MD; Stidley, CA; Tellez, CS; Tesfaigzi, Y | 1 |
| Ikezoe, T; Nishioka, C; Udaka, K; Yang, J; Yokoyama, A | 1 |
| Baylin, SB; Belinsky, SA; Brock, MV; Coleman, B; Delgado, IE; Franco, N; Herman, JG; Hooker, CM; Juergens, RA; Lee, B; Murphy, SC; Rodgers, K; Rudek, MA; Rudin, CM; Sebree, R; Tsai, S; Vendetti, FP; Wrangle, J; Zhao, M | 1 |
| Wolfson, W | 1 |
| Belinsky, SA; Cheng, YS; Grimes, MJ; Kuehl, PJ; March, TH; Picchi, MA; Reed, MD; Tellez, CS; Tessema, M | 1 |
| Czader, M; Erba, HP; Figueroa, ME; Gabrilove, J; Gore, SD; Greenberg, PL; Herman, J; Juckett, M; Ketterling, R; Litzow, M; Malick, L; Melnick, A; Paietta, E; Prebet, T; Smith, MR; Sun, Z; Tallman, MS | 1 |
| Belinsky, SA; Grimes, MJ; Liu, Y; March, TH; Oganesian, A; Picchi, MA; Reed, MD; Taverna, P; Tellez, CS | 1 |
| Fanger, G; Knox, S; Oronsky, B; Oronsky, N; Scicinski, J | 1 |
| Blosser, RL; Diaz, LA; Kim, K; Kinzler, KW; Li, Z; Liu, Q; Papadopoulos, N; Skora, AD; Tam, AJ; Vogelstein, B; Zhou, S | 1 |
| Baylin, SB; Dobromilskaya, I; Easwaran, H; Huang, P; Poirier, JT; Rudin, CM; Topper, M; Vendetti, FP; Wrangle, J | 1 |
| Hattori, N; Takeshima, H; Ushijima, T; Wakabayashi, M; Yamashita, S | 1 |
| Ahrens, TD; Boerries, M; Busch, H; Follo, M; Hembach, S; Hoeppner, J; Hopt, UT; Lassmann, S; Ostendorp, J; Timme, S; Werner, M | 1 |
| Czader, M; Erba, HP; Figueroa, M; Gabrilove, J; Gore, SD; Greenberg, P; Herman, J; Juckett, M; Ketterling, RP; Litzow, M; Malick, L; Paietta, E; Prebet, T; Smith, MR; Sun, Z; Tallman, MS; Zeidan, A | 1 |
| Weintraub, K | 1 |
| Carter, CA; Day, RM; Lybeck, M; Oronsky, A; Oronsky, B; Oronsky, N; Richard, P; Scicinski, J; Zeman, K | 1 |
| Iwaisako, K; Kawashima, M; Kawata, Y; Kurebayashi, J; Nishimura, T; Noda, M; Shi, G; Toi, M; Yoshida, Y; Yoshikawa, K; Yuki, K | 1 |
| Bai, J; Du, Z; Feng, X; Li, A; Liu, B; Luan, J; Song, J; Sun, X; Wang, H; Zhang, L | 1 |
| Adkins, D; Ahuja, N; Azad, NS; Bahary, N; Baylin, S; Brown, T; Donehower, R; Easwaran, H; El-Khoueiry, A; Erlichman, C; Flynn, P; Jones, PA; Kamel, I; Kim, G; Laird, PW; Medvari, P; Oberg, AL; Picus, J; Piekarz, R; Pitot, HC; Sharma, A; Shen, H; Weisenberger, DJ; Yin, J | 1 |
| Arend, RC; Buchsbaum, DJ; Forero, A; Katre, A; Londoño, A; Meza-Perez, S; Norian, LA; Peabody, JE; Randall, TD; Smith, HJ; Straughn, JM; Turner, TB | 1 |
| Carraway, HE; Gore, SD; Keefer, J; Prebet, T; Press, KR; Sakoian, S; Uy, N | 1 |
| Battafarano, RJ; Baylin, SB; Brahmer, JR; Brock, MV; Broderick, SR; Bush, EL; Cai, Y; Cattaneo, SM; Cui, Y; Day, CP; Easwaran, H; Forde, PM; Housseau, F; Huang, P; Hulbert, A; Jiao, X; Juergens, RA; Kim, K; Kim, YJ; Kong, X; Lee, B; Li, H; Li, S; Lu, Z; Margolick, JB; Mei, Y; Nelkin, BD; Pardoll, DM; Riemer, JB; Rodgers, K; Rudin, CM; Shen, L; Tao, Y; Topper, MJ; Vaz, M; Wang, KK; Wang, Y; Wrangle, J; Xia, L; Xie, W; Yang, SC; Yen, RC; Zahnow, CA; Zhang, B; Zhang, H; Zhang, W; Zou, J | 1 |
| Babasaki, T; Harada, K; Hayashi, T; Maruyama, R; Murai, J; Pham, QT; Pommier, Y; Sakamoto, N; Sekino, Y; Sentani, K; Takashima, T; Takeda, M; Taniyama, D; Ukai, S; Yasui, W | 1 |
2 review(s) available for azacitidine and entinostat
| Article | Year |
|---|---|
Episensitization: therapeutic tumor resensitization by epigenetic agents: a review and reassessment.
Topics: Animals; Antineoplastic Agents; Azacitidine; Azetidines; Benzamides; Decitabine; DNA Modification Methylases; Drug Resistance, Neoplasm; Epigenesis, Genetic; Histone Deacetylase Inhibitors; Humans; Hydroxamic Acids; Neoplasms; Nitro Compounds; Oxidative Stress; Pyridines; Vorinostat | 2014 |
Addressing the elephant in the room, therapeutic resistance in non-small cell lung cancer, with epigenetic therapies.
Topics: Antibodies, Monoclonal; Azacitidine; Azetidines; Benzamides; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; CpG Islands; Disease Progression; DNA Methylation; Drug Resistance, Neoplasm; Epigenesis, Genetic; Histones; Humans; Hydralazine; Immunotherapy; Lung Neoplasms; Molecular Targeted Therapy; Mutation; Neoplasm Recurrence, Local; Nitro Compounds; Nivolumab; Prognosis; Pyridines; Treatment Outcome; Valproic Acid | 2016 |
5 trial(s) available for azacitidine and entinostat
| Article | Year |
|---|---|
Early epigenetic changes and DNA damage do not predict clinical response in an overlapping schedule of 5-azacytidine and entinostat in patients with myeloid malignancies.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Benzamides; Cytogenetic Analysis; DNA Damage; Drug Administration Schedule; Epigenesis, Genetic; Female; Hematologic Neoplasms; Humans; Male; Middle Aged; Prognosis; Pyridines; Time Factors | 2009 |
Combination epigenetic therapy has efficacy in patients with refractory advanced non-small cell lung cancer.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Benzamides; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; Cohort Studies; Combined Modality Therapy; Disease Progression; Disease-Free Survival; DNA Methylation; Epigenesis, Genetic; Female; Genetic Therapy; Histones; Humans; Lung Neoplasms; Male; Middle Aged; Pyridines | 2011 |
Prolonged administration of azacitidine with or without entinostat for myelodysplastic syndrome and acute myeloid leukemia with myelodysplasia-related changes: results of the US Leukemia Intergroup trial E1905.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Benzamides; Drug Administration Schedule; Female; Humans; Leukemia, Myeloid, Acute; Leukemia, Myelomonocytic, Chronic; Male; Middle Aged; Myelodysplastic Syndromes; Pyridines; Survival Analysis; Treatment Outcome | 2014 |
Azacitidine with or without Entinostat for the treatment of therapy-related myeloid neoplasm: further results of the E1905 North American Leukemia Intergroup study.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Benzamides; Drug Administration Schedule; Female; Humans; Kaplan-Meier Estimate; Leukemia, Myeloid, Acute; Male; Middle Aged; Myelodysplastic Syndromes; Neoplasms, Second Primary; Pyridines; Treatment Outcome | 2016 |
Combination epigenetic therapy in metastatic colorectal cancer (mCRC) with subcutaneous 5-azacitidine and entinostat: a phase 2 consortium/stand up 2 cancer study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Benzamides; Cell Line, Tumor; Cohort Studies; Colorectal Neoplasms; DNA Methylation; Drug Administration Schedule; Epigenesis, Genetic; Female; HCT116 Cells; Humans; Male; Middle Aged; Pyridines; Survival Analysis; Treatment Outcome | 2017 |
23 other study(ies) available for azacitidine and entinostat
| Article | Year |
|---|---|
Identification of potent Yes1 kinase inhibitors using a library screening approach.
Topics: Binding Sites; Cell Line; Cell Survival; Drug Design; Humans; Hydrogen Bonding; Molecular Docking Simulation; Protein Kinase Inhibitors; Protein Structure, Tertiary; Proto-Oncogene Proteins c-yes; Small Molecule Libraries; Structure-Activity Relationship | 2013 |
In vivo quantitative high-throughput screening for drug discovery and comparative toxicology.
Topics: Animals; Caenorhabditis elegans; Drug Discovery; High-Throughput Screening Assays; Humans; Proteomics; Small Molecule Libraries | 2023 |
Induction of fetal hemoglobin expression by the histone deacetylase inhibitor apicidin.
Topics: Amides; Azacitidine; Benzamides; Butyrates; Enzyme Inhibitors; Fetal Hemoglobin; Gene Expression Regulation; Gene Expression Regulation, Leukemic; Globins; Histone Deacetylase Inhibitors; Histone Deacetylases; Histones; Humans; Hydroxamic Acids; Hydroxyurea; Imidazoles; K562 Cells; MAP Kinase Signaling System; Mitogen-Activated Protein Kinases; Neoplasm Proteins; p38 Mitogen-Activated Protein Kinases; Peptides, Cyclic; Phenylbutyrates; Pyridines; Vorinostat | 2003 |
MAGE-A9 mRNA and protein expression in bladder cancer.
Topics: Antibodies, Monoclonal; Antigens, Neoplasm; Azacitidine; Benzamides; Cell Line, Tumor; Decitabine; Gene Expression; Histone Deacetylase Inhibitors; Humans; Immunohistochemistry; Male; Neoplasm Proteins; Phenylbutyrates; Protein Isoforms; Pyridines; RNA, Messenger; Testicular Neoplasms; Urinary Bladder Neoplasms | 2007 |
Potentiation of reactive oxygen species is a marker for synergistic cytotoxicity of MS-275 and 5-azacytidine in leukemic cells.
Topics: Acetylation; Antimetabolites, Antineoplastic; Apoptosis; Azacitidine; Benzamides; Biomarkers; Caspase 3; Drug Synergism; Enzyme Inhibitors; Glutathione; Histone Deacetylase Inhibitors; Histones; Humans; Jurkat Cells; Leukemia; Pyridines; Reactive Oxygen Species | 2008 |
Inhibitors of poly ADP-ribose polymerase (PARP) induce apoptosis of myeloid leukemic cells: potential for therapy of myeloid leukemia and myelodysplastic syndromes.
Topics: Apoptosis; Azacitidine; Benzamides; Butyrates; Cell Cycle; Cell Line; Cell Line, Tumor; Cell Survival; Decitabine; DNA Modification Methylases; DNA Repair; Drug Synergism; Flow Cytometry; Fluorescent Antibody Technique; Fluorobenzenes; Histone Acetyltransferases; HL-60 Cells; Humans; Hydroxamic Acids; Immunohistochemistry; K562 Cells; Leukemia, Myeloid; Myelodysplastic Syndromes; Phenanthrenes; Phthalazines; Poly(ADP-ribose) Polymerase Inhibitors; Poly(ADP-ribose) Polymerases; Pyridines; U937 Cells | 2009 |
Three epigenetic drugs up-regulate homeobox gene Rhox5 in cancer cells through overlapping and distinct molecular mechanisms.
Topics: Animals; Arsenic Trioxide; Arsenicals; Azacitidine; Benzamides; Cell Line, Tumor; Decitabine; DNA Modification Methylases; Epigenesis, Genetic; Genes, Homeobox; Growth Inhibitors; Histone Deacetylase Inhibitors; Homeodomain Proteins; Humans; Male; Mice; Oxides; Pyridines; Transcription Factors; Up-Regulation | 2009 |
Combination therapy with vidaza and entinostat suppresses tumor growth and reprograms the epigenome in an orthotopic lung cancer model.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Azacitidine; Benzamides; Cell Line, Tumor; Cyclin-Dependent Kinase Inhibitor p21; DNA (Cytosine-5-)-Methyltransferase 1; DNA (Cytosine-5-)-Methyltransferases; DNA Methylation; Epigenesis, Genetic; Gene Expression Profiling; Histone Deacetylase Inhibitors; Humans; Lung Neoplasms; Male; Pyridines; Rats; Signal Transduction; Xenograft Model Antitumor Assays | 2011 |
Simultaneous inhibition of DNA methyltransferase and histone deacetylase induces p53-independent apoptosis via down-regulation of Mcl-1 in acute myelogenous leukemia cells.
Topics: Apoptosis; Azacitidine; Benzamides; Blotting, Western; Cell Cycle; Cell Proliferation; Cyclin-Dependent Kinase Inhibitor p21; Decitabine; DNA Modification Methylases; Drug Therapy, Combination; Enzyme Inhibitors; Epigenomics; Flow Cytometry; Gene Expression Regulation, Neoplastic; Histone Deacetylase Inhibitors; Humans; Leukemia, Myeloid, Acute; Mutation, Missense; Myeloid Cell Leukemia Sequence 1 Protein; Proto-Oncogene Proteins c-bcl-2; Pyridines; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; RNA, Small Interfering; Tumor Cells, Cultured; Tumor Suppressor Protein p53 | 2011 |
Epigenetic cancer therapies emerge out of the lab into the limelight.
Topics: Antineoplastic Agents; Azacitidine; Benzamides; Clinical Trials as Topic; Depsipeptides; Drug Resistance, Neoplasm; Epigenomics; Histone Deacetylase Inhibitors; Humans; Hydroxamic Acids; Neoplasms; Pyridines; Vorinostat | 2013 |
Aerosolised 5-azacytidine suppresses tumour growth and reprogrammes the epigenome in an orthotopic lung cancer model.
Topics: Administration, Inhalation; Aerosols; Animals; Antimetabolites, Antineoplastic; Azacitidine; Benzamides; Cytidine Deaminase; DNA Methylation; Epigenesis, Genetic; Histone Deacetylase Inhibitors; Lung Neoplasms; Male; Neoplasm Transplantation; Pyridines; Rats; Tumor Burden | 2013 |
SGI-110 and entinostat therapy reduces lung tumor burden and reprograms the epigenome.
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Benzamides; Biomarkers, Tumor; Epigenesis, Genetic; Gene Expression Profiling; Immunologic Factors; Lung Neoplasms; Male; Oligonucleotide Array Sequence Analysis; Pyridines; Rats; Rats, Nude; Real-Time Polymerase Chain Reaction; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Tumor Burden | 2014 |
Eradication of metastatic mouse cancers resistant to immune checkpoint blockade by suppression of myeloid-derived cells.
Topics: Animals; Antibodies, Monoclonal; Azacitidine; Benzamides; Cell Line, Tumor; Colorectal Neoplasms; Combined Modality Therapy; CTLA-4 Antigen; Epigenesis, Genetic; Female; Histone Deacetylase Inhibitors; Humans; Immunotherapy; Mammary Neoplasms, Experimental; Mice; Mice, Inbred BALB C; Myeloid Cells; Neoplasm Metastasis; Phosphoinositide-3 Kinase Inhibitors; Programmed Cell Death 1 Receptor; Pyridines | 2014 |
Evaluation of azacitidine and entinostat as sensitization agents to cytotoxic chemotherapy in preclinical models of non-small cell lung cancer.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Benzamides; Camptothecin; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Survival; DNA Methylation; Drug Evaluation, Preclinical; Epigenesis, Genetic; Female; Histones; Humans; Irinotecan; Lung Neoplasms; Mice; Mice, Inbred NOD; Mice, SCID; Neoplasm Transplantation; Pyridines | 2015 |
Identification of coexistence of DNA methylation and H3K27me3 specifically in cancer cells as a promising target for epigenetic therapy.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Benzamides; Cell Proliferation; Decitabine; DNA Methylation; Enhancer of Zeste Homolog 2 Protein; Enzyme Inhibitors; Epigenesis, Genetic; Female; Gene Expression Regulation, Neoplastic; HCT116 Cells; Histone Deacetylase Inhibitors; Histones; Humans; Indoles; Insulin-Like Growth Factor Binding Proteins; Intercellular Signaling Peptides and Proteins; Male; MCF-7 Cells; Membrane Proteins; Mice; Mice, Inbred BALB C; Mice, Nude; Neoplasms; Polycomb Repressive Complex 2; Promoter Regions, Genetic; Pyridines; Pyridones; Xenograft Model Antitumor Assays | 2015 |
Selective inhibition of esophageal cancer cells by combination of HDAC inhibitors and Azacytidine.
Topics: Acetylation; Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Azacitidine; Benzamides; Carcinoma, Squamous Cell; Cell Cycle Checkpoints; Cell Line, Tumor; Cell Movement; Cell Survival; Decitabine; Depsipeptides; DNA (Cytosine-5-)-Methyltransferase 1; DNA (Cytosine-5-)-Methyltransferases; DNA Damage; Esophageal Neoplasms; Esophageal Squamous Cell Carcinoma; Histone Deacetylase Inhibitors; Histones; Humans; Hydroxamic Acids; Pyridines; Transcriptome; Vorinostat | 2015 |
Take two: Combining immunotherapy with epigenetic drugs to tackle cancer.
Topics: Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Benzamides; Carcinoma, Non-Small-Cell Lung; Epigenesis, Genetic; Humans; Immunotherapy; Lung Neoplasms; Nivolumab; Pyridines | 2016 |
Pattern of RECK CpG methylation as a potential marker for predicting breast cancer prognosis and drug-sensitivity.
Topics: Antineoplastic Agents; Azacitidine; Benzamides; Breast Neoplasms; CpG Islands; Decitabine; DNA Methylation; Dose-Response Relationship, Drug; Epigenesis, Genetic; Exons; Female; GPI-Linked Proteins; Histone Deacetylase Inhibitors; Humans; MCF-7 Cells; Methotrexate; Middle Aged; Neoplasm Grading; Neoplasm Staging; Promoter Regions, Genetic; Pyridines; Time Factors | 2016 |
Promoter methylation status of tumor suppressor genes and inhibition of expression of DNA methyltransferase 1 in non-small cell lung cancer.
Topics: Animals; Azacitidine; Benzamides; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Decitabine; DNA (Cytosine-5-)-Methyltransferase 1; DNA (Cytosine-5-)-Methyltransferases; DNA Methylation; Enzyme Inhibitors; Gene Expression Regulation, Neoplastic; Genes, Tumor Suppressor; Histone Deacetylase Inhibitors; Humans; Male; Mice, Inbred BALB C; Mice, Nude; Promoter Regions, Genetic; Pyridines | 2016 |
Epigenetic modifiers upregulate MHC II and impede ovarian cancer tumor growth.
Topics: Animals; Antimetabolites, Antineoplastic; Azacitidine; Benzamides; Cell Line, Tumor; Disease Models, Animal; DNA Methylation; Dose-Response Relationship, Drug; Drug Synergism; Epigenesis, Genetic; Female; Gene Expression Regulation, Neoplastic; Histocompatibility Antigens Class II; Histone Deacetylase Inhibitors; Humans; Hydroxamic Acids; Indoles; Mice; Ovarian Neoplasms; Panobinostat; Pyridines; RNA, Messenger; Transcription, Genetic; Tumor Burden; Xenograft Model Antitumor Assays | 2017 |
Clinical evaluation of combined azacitidine and entinostat on the induction of fetal hemoglobin in patients with acute myeloid leukemias and myelodysplastic syndromes.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Benzamides; Clinical Trials, Phase I as Topic; Female; Fetal Hemoglobin; Follow-Up Studies; Humans; Leukemia, Myeloid, Acute; Male; Myelodysplastic Syndromes; Prognosis; Pyridines | 2018 |
Epigenetic therapy inhibits metastases by disrupting premetastatic niches.
Topics: Animals; Azacitidine; Benzamides; Cell Differentiation; Cell Movement; Chemotherapy, Adjuvant; Disease Models, Animal; Down-Regulation; Epigenesis, Genetic; Genetic Therapy; Mice; Myeloid-Derived Suppressor Cells; Neoplasm Metastasis; Neoplasms; Pyridines; Receptors, CCR2; Receptors, Interleukin-8B; Tumor Microenvironment | 2020 |
Prognostic impact of Schlafen 11 in bladder cancer patients treated with platinum-based chemotherapy.
Topics: Aged; Antineoplastic Agents; Azacitidine; Benzamides; Biomarkers, Tumor; Cell Line, Tumor; Chemotherapy, Adjuvant; Cisplatin; Drug Resistance, Neoplasm; Drug Synergism; Female; GATA3 Transcription Factor; Humans; Male; Nuclear Proteins; Platinum; Prognosis; Pyridines; Urinary Bladder Neoplasms | 2022 |